271 related articles for article (PubMed ID: 22180432)
21. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
al-Katib A; Mohammad RM; Dan M; Hussein ME; Akhtar A; Pettit GR; Sensenbrenner LL
Exp Hematol; 1993 Jan; 21(1):61-5. PubMed ID: 8093352
[TBL] [Abstract][Full Text] [Related]
22. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
23. BL22 and lymphoid malignancies.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2006; 19(4):685-99. PubMed ID: 16997177
[TBL] [Abstract][Full Text] [Related]
24. Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22.
Chen WC; Sigal DS; Saven A; Paulson JC
Leuk Lymphoma; 2012 Feb; 53(2):208-10. PubMed ID: 21756025
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
[TBL] [Abstract][Full Text] [Related]
26. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin.
Ho M; Kreitman RJ; Onda M; Pastan I
J Biol Chem; 2005 Jan; 280(1):607-17. PubMed ID: 15491997
[TBL] [Abstract][Full Text] [Related]
27. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
28. Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells.
Drexler HG; Gignac SM; Jones RA; Scott CS; Pettit GR; Hoffbrand AV
Blood; 1989 Oct; 74(5):1747-57. PubMed ID: 2506950
[TBL] [Abstract][Full Text] [Related]
29. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
30. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
32. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
[TBL] [Abstract][Full Text] [Related]
33. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
34. Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
van Horssen PJ; van Oosterhout YV; Evers S; Backus HH; van Oijen MG; Bongaerts R; de Witte T; Preijers FW
Leukemia; 1999 Feb; 13(2):241-9. PubMed ID: 10025898
[TBL] [Abstract][Full Text] [Related]
35. Nuclear overexpression of lymphoid-enhancer-binding factor 1 identifies chronic lymphocytic leukemia/small lymphocytic lymphoma in small B-cell lymphomas.
Tandon B; Peterson L; Gao J; Nelson B; Ma S; Rosen S; Chen YH
Mod Pathol; 2011 Nov; 24(11):1433-43. PubMed ID: 21685909
[TBL] [Abstract][Full Text] [Related]
36. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.
Schmohl JU; Todhunter D; Taras E; Bachanova V; Vallera DA
Toxins (Basel); 2018 Jan; 10(1):. PubMed ID: 29316610
[TBL] [Abstract][Full Text] [Related]
37. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms.
Wojciechowski W; Li H; Marshall S; Dell'Agnola C; Espinoza-Delgado I
J Immunol; 2005 Jun; 174(12):7859-68. PubMed ID: 15944291
[TBL] [Abstract][Full Text] [Related]
38. Approach to the patient after relapse of hairy cell leukemia.
Kreitman RJ; Fitzgerald DJ; Pastan I
Leuk Lymphoma; 2009 Oct; 50 Suppl 1(Suppl 1):32-7. PubMed ID: 19814696
[TBL] [Abstract][Full Text] [Related]
39. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
40. Two Saporin-Containing Immunotoxins Specific for CD20 and CD22 Show Different Behavior in Killing Lymphoma Cells.
Polito L; Mercatelli D; Bortolotti M; Maiello S; Djemil A; Battelli MG; Bolognesi A
Toxins (Basel); 2017 May; 9(6):. PubMed ID: 28556822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
